<ul>
<li>异常高的交易量指向这些股票的上涨潜力</li>
</ul>
<p>Candel Therapeutics, Inc.（NASDAQ:CADL - 免费报告）- Brookline Capital Management 的股票分析师在 2023 年 12 月 7 日（星期日）发布的报告中发布了 Candel Therapeutics 的 2025 年第四季度收益预估。Brookline Capital Management 的分析师 K. Dolliver 预计该公司本季度每股收益为（$0.22）。Candel Therapeutics 当前全年的共识收益预估为每股（$1.47）。</p>
<p>获取 <strong>Candel Therapeutics</strong> 的提醒：</p>
<p>其他几家券商最近也发布了关于 CADL 的报告。Lifesci Capital 在 2023 年 10 月 21 日（星期二）对 Candel Therapeutics 进行了覆盖。他们对该股票给予了 “跑赢大盘” 的评级，并设定了$16.00 的目标价。花旗集团在 2023 年 11 月 14 日（星期五）将 Candel Therapeutics 的目标价从$25.00 下调至$24.00，并对该股票设定了 “买入” 评级。Stephens 在周一重新发布了 “增持” 评级，并对 Candel Therapeutics 的股票设定了$15.00 的目标价。美国银行在 2023 年 9 月 3 日（星期三）将 Candel Therapeutics 的股票评级从 “买入” 下调至 “中性”，并将该股票的目标价从$13.00 下调至$7.00。最后，Wall Street Zen 在 2023 年 11 月 15 日（星期六）的研究报告中将 Candel Therapeutics 的股票评级从 “持有” 下调至 “卖出”。一位股票研究分析师对该股票给予了强烈买入评级，五位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Candel Therapeutics 目前的共识评级为 “适度买入”，共识目标价为$18.33。</p>
<p><strong>查看我们对 Candel Therapeutics 的最新股票分析</strong></p>
<h2>Candel Therapeutics 的价格表现</h2>
<p>NASDAQ:CADL 的股票在周三开盘价为$5.66。该公司的市值为$3.1073 亿，市盈率为-9.93，贝塔值为-0.92。Candel Therapeutics 的 52 周低点为$4.25，52 周高点为$14.60。该公司的债务与股本比率为 0.01，速动比率为 8.25，流动比率为 8.25。该公司的 50 日移动平均价格为$5.22，200 日移动平均价格为$5.50。</p>
<p>Candel Therapeutics（NASDAQ:CADL - 获取免费报告）最近在 2023 年 11 月 13 日（星期四）发布了季度收益结果。该公司报告本季度每股收益为（$0.21），低于分析师的共识预估（$0.17）$0.04。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近增加或减少了在 CADL 的持股。BNP Paribas Financial Markets 在第三季度将其在 Candel Therapeutics 的持股增加了 128.2%。BNP Paribas Financial Markets 现在拥有 7901 股该公司的股票，价值$40,000，在此期间又购买了 4439 股。Tower Research Capital LLC TRC 在第二季度将其在 Candel Therapeutics 的持股增加了 361.7%。Tower Research Capital LLC TRC 现在拥有 9608 股该公司的股票，价值$49,000，在此期间又购买了 7527 股。Invesco Ltd.在第一季度购买了 Candel Therapeutics 的新股份，价值$59,000。AlphaQuest LLC 在第一季度购买了 Candel Therapeutics 的新股份，价值$61,000。最后，Taylor Financial Group Inc.在第三季度将其在 Candel Therapeutics 的持股增加了 36.0%。Taylor Financial Group Inc.现在拥有 13600 股该公司的股票，价值$69,000，在上个季度又获得了 3600 股。对冲基金和其他机构投资者持有该公司 13.93% 的股票。</p>
<h2>Candel Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Candel Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于为癌症患者开发免疫疗法。它开发的 CAN-2409 目前正在进行针对胰腺癌的二期临床试验；针对前列腺癌的三期临床试验；以及针对肺癌的二期临床试验，并已完成针对高等级胶质瘤的 Ib/II 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Candel Therapeutics 更好</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>内部人士正在出售这三只股票——原因在这里</li>
<li>道琼斯的狗策略是什么？概述和示例</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>股票市场升级：它们是什么？</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆炸</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Candel Therapeutics 吗？</h2>
<p>在你考虑 Candel Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Candel Therapeutics 并不在名单上。</p>
<p>虽然 Candel Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CADL

<p>Brookline Capital Management 预计 Candel Therapeutics 在 2025 年第四季度每股收益为（$0.22）。该股票的共识评级为 “适度买入”，目标价格为 $18.33。最近的评级包括 “跑赢大盘” 和 “买入”，但美国银行将其下调至 “中性”。机构投资者已调整其持股比例，对冲基金持有该股票的 13.93%。Candel Therapeutics 开发癌症免疫疗法，目前有多个正在进行的临床试验</p>

<ul>
<li>Unusually High Volume Points to Upside in These Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>异常高的交易量指向这些股票的上涨潜力</li>
</ul>
</div><p>Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday, December 7th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.22) per share for the quarter. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share.</p>
<div class="lb-trans"><p>Candel Therapeutics, Inc.（NASDAQ:CADL - 免费报告）- Brookline Capital Management 的股票分析师在 2023 年 12 月 7 日（星期日）发布的报告中发布了 Candel Therapeutics 的 2025 年第四季度收益预估。Brookline Capital Management 的分析师 K. Dolliver 预计该公司本季度每股收益为（$0.22）。Candel Therapeutics 当前全年的共识收益预估为每股（$1.47）。</p>
</div><p>Get <strong>Candel Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Candel Therapeutics</strong> 的提醒：</p>
</div><p>Several other brokerages have also recently issued reports on CADL. Lifesci Capital assumed coverage on Candel Therapeutics in a report on Tuesday, October 21st. They issued an &#34;outperform&#34; rating and a $16.00 target price on the stock. Citigroup decreased their price objective on Candel Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, November 14th. Stephens reissued an &#34;overweight&#34; rating and issued a $15.00 target price on shares of Candel Therapeutics in a report on Monday. Bank of America cut shares of Candel Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and reduced their price target for the stock from $13.00 to $7.00 in a research report on Wednesday, September 3rd. Finally, Wall Street Zen lowered shares of Candel Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Candel Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $18.33.</p>
<div class="lb-trans"><p>其他几家券商最近也发布了关于 CADL 的报告。Lifesci Capital 在 2023 年 10 月 21 日（星期二）对 Candel Therapeutics 进行了覆盖。他们对该股票给予了 “跑赢大盘” 的评级，并设定了$16.00 的目标价。花旗集团在 2023 年 11 月 14 日（星期五）将 Candel Therapeutics 的目标价从$25.00 下调至$24.00，并对该股票设定了 “买入” 评级。Stephens 在周一重新发布了 “增持” 评级，并对 Candel Therapeutics 的股票设定了$15.00 的目标价。美国银行在 2023 年 9 月 3 日（星期三）将 Candel Therapeutics 的股票评级从 “买入” 下调至 “中性”，并将该股票的目标价从$13.00 下调至$7.00。最后，Wall Street Zen 在 2023 年 11 月 15 日（星期六）的研究报告中将 Candel Therapeutics 的股票评级从 “持有” 下调至 “卖出”。一位股票研究分析师对该股票给予了强烈买入评级，五位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Candel Therapeutics 目前的共识评级为 “适度买入”，共识目标价为$18.33。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Candel Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Candel Therapeutics 的最新股票分析</strong></p>
</div><h2>Candel Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Candel Therapeutics 的价格表现</h2>
</div><p>Shares of NASDAQ:CADL opened at $5.66 on Wednesday. The firm has a market cap of $310.73 million, a price-to-earnings ratio of -9.93 and a beta of -0.92. Candel Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $14.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.25 and a current ratio of 8.25. The firm has a fifty day moving average price of $5.22 and a 200 day moving average price of $5.50.</p>
<div class="lb-trans"><p>NASDAQ:CADL 的股票在周三开盘价为$5.66。该公司的市值为$3.1073 亿，市盈率为-9.93，贝塔值为-0.92。Candel Therapeutics 的 52 周低点为$4.25，52 周高点为$14.60。该公司的债务与股本比率为 0.01，速动比率为 8.25，流动比率为 8.25。该公司的 50 日移动平均价格为$5.22，200 日移动平均价格为$5.50。</p>
</div><p>Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04).</p>
<div class="lb-trans"><p>Candel Therapeutics（NASDAQ:CADL - 获取免费报告）最近在 2023 年 11 月 13 日（星期四）发布了季度收益结果。该公司报告本季度每股收益为（$0.21），低于分析师的共识预估（$0.17）$0.04。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in CADL. BNP Paribas Financial Markets boosted its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock valued at $40,000 after buying an additional 4,439 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after purchasing an additional 7,527 shares during the period. Invesco Ltd. purchased a new stake in shares of Candel Therapeutics in the 1st quarter worth $59,000. AlphaQuest LLC bought a new position in shares of Candel Therapeutics during the 1st quarter worth $61,000. Finally, Taylor Financial Group Inc. raised its holdings in shares of Candel Therapeutics by 36.0% in the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company's stock valued at $69,000 after acquiring an additional 3,600 shares in the last quarter. Hedge funds and other institutional investors own 13.93% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了在 CADL 的持股。BNP Paribas Financial Markets 在第三季度将其在 Candel Therapeutics 的持股增加了 128.2%。BNP Paribas Financial Markets 现在拥有 7901 股该公司的股票，价值$40,000，在此期间又购买了 4439 股。Tower Research Capital LLC TRC 在第二季度将其在 Candel Therapeutics 的持股增加了 361.7%。Tower Research Capital LLC TRC 现在拥有 9608 股该公司的股票，价值$49,000，在此期间又购买了 7527 股。Invesco Ltd.在第一季度购买了 Candel Therapeutics 的新股份，价值$59,000。AlphaQuest LLC 在第一季度购买了 Candel Therapeutics 的新股份，价值$61,000。最后，Taylor Financial Group Inc.在第三季度将其在 Candel Therapeutics 的持股增加了 36.0%。Taylor Financial Group Inc.现在拥有 13600 股该公司的股票，价值$69,000，在上个季度又获得了 3600 股。对冲基金和其他机构投资者持有该公司 13.93% 的股票。</p>
</div><h2>Candel Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Candel Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.</p>
<div class="lb-trans"><p>Candel Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于为癌症患者开发免疫疗法。它开发的 CAN-2409 目前正在进行针对胰腺癌的二期临床试验；针对前列腺癌的三期临床试验；以及针对肺癌的二期临床试验，并已完成针对高等级胶质瘤的 Ib/II 期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Candel Therapeutics</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Insiders Are Selling These 3 Stocks—Here’s Why</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>Stock Market Upgrades: What Are They?</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Candel Therapeutics 更好</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>内部人士正在出售这三只股票——原因在这里</li>
<li>道琼斯的狗策略是什么？概述和示例</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>股票市场升级：它们是什么？</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆炸</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Candel Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Candel Therapeutics 吗？</h2>
</div><p>Before you consider Candel Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Candel Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Candel Therapeutics 并不在名单上。</p>
</div><p>While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Candel Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Brookline Capital Management 对 CADL 第四季度财报发表看法